Concepedia

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham, Edward Keystone, Roy Fleischmann, Daniel E. Furst, Katherine Macey, Marianne T. Sweetser, Ariella Kelman, Ravi Rao

The Journal of Rheumatology · 2010 · 283 citations · 31 references

DOIFull text

Open access

Abstract

In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course.

References

31

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold et al. · New England Journal of Medicine · 2008 · 2.4K citations · Full text

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska et al. · Arthritis & Rheumatism · 2006 · 1K citations